TR200102499T2 - Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi - Google Patents

Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi

Info

Publication number
TR200102499T2
TR200102499T2 TR2001/02499T TR200102499T TR200102499T2 TR 200102499 T2 TR200102499 T2 TR 200102499T2 TR 2001/02499 T TR2001/02499 T TR 2001/02499T TR 200102499 T TR200102499 T TR 200102499T TR 200102499 T2 TR200102499 T2 TR 200102499T2
Authority
TR
Turkey
Prior art keywords
cyclooxygenase
inhibitor
neoplasia
treatment
combination therapy
Prior art date
Application number
TR2001/02499T
Other languages
English (en)
Inventor
P. Mckearn John
Gordon Gary
J.Cunningham James
T. Gately Stephen
T. Koki Alane
L. Masferrer Jamie
Original Assignee
G.D.Searle &Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D.Searle &Co. filed Critical G.D.Searle &Co.
Publication of TR200102499T2 publication Critical patent/TR200102499T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Bu bulus bir memelide neoplazi bozukluklarini bir siklooksijenaz-2 inhibitörü ve bir antineoplastik ajan kombinasyonu kullanarak tedavi etmek veya önlemek için yöntemler sunmaktadir.
TR2001/02499T 1998-12-23 1999-12-22 Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi TR200102499T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11378698P 1998-12-23 1998-12-23

Publications (1)

Publication Number Publication Date
TR200102499T2 true TR200102499T2 (tr) 2001-12-21

Family

ID=22351515

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02499T TR200102499T2 (tr) 1998-12-23 1999-12-22 Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi

Country Status (20)

Country Link
US (1) US6689787B1 (tr)
EP (8) EP1140192B1 (tr)
JP (8) JP2002532563A (tr)
KR (2) KR20010110310A (tr)
CN (3) CN1398189A (tr)
AT (1) ATE322290T1 (tr)
AU (8) AU2592600A (tr)
BR (2) BR9916536A (tr)
CA (8) CA2356606A1 (tr)
CZ (2) CZ20012320A3 (tr)
DE (1) DE69930764D1 (tr)
EA (2) EA200100573A1 (tr)
HU (2) HUP0104747A3 (tr)
IL (2) IL143870A0 (tr)
MX (1) MXPA01006499A (tr)
NO (2) NO20013156L (tr)
PL (2) PL350291A1 (tr)
TR (1) TR200102499T2 (tr)
WO (8) WO2000038730A2 (tr)
ZA (2) ZA200105055B (tr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US7029652B2 (en) * 1998-09-16 2006-04-18 The Regents Of The University Of California Method of treating tumors
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
CA2362230A1 (en) * 1999-02-08 2000-08-10 G.D. Searle & Co. Sulfamato hydroxamic acid metalloprotease inhibitor
KR20020009610A (ko) * 1999-05-12 2002-02-01 윌리암스 로저 에이 매트릭스 메탈로프로테아제 억제제로서의 히드록삼산 유도체
JP2002544229A (ja) 1999-05-17 2002-12-24 アイレックス オンコロジー， インコーポレイテッド 癌の化学的予防および治療のために組み合わせたｄｆｍｏおよびセレコキシブ
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US7465754B1 (en) 1999-09-15 2008-12-16 Wyeth Method of potentiating chemotherapy and treating solid tumors
JP2003509383A (ja) * 1999-09-15 2003-03-11 ワイス 化学療法を強化し、充実性腫瘍を治療する方法
AU1767001A (en) * 1999-11-15 2001-05-30 Advanced Research And Technology Institute, Inc. Use of nsaids for the treatment of pancreatic cancer
CA2399001C (en) * 2000-02-03 2010-07-20 Eisai Co., Ltd. Integrin expression inhibitor
WO2001064110A1 (en) * 2000-02-28 2001-09-07 Zila, Inc. Method for detecting and killing epithelial cancer cells
MXPA02009351A (es) 2000-03-24 2003-02-12 Novartis Ag Tratamiento mejorado de neovascularizacion.
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
WO2001096307A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
AU2001273115C1 (en) 2000-06-29 2009-03-26 Quick Med Technologies, Inc. Cosmetic composition and method
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
CA2419590A1 (en) * 2000-09-08 2002-03-14 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent
AR034142A1 (es) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
WO2002072106A2 (en) * 2001-01-26 2002-09-19 Pharmacia Italia Spa Combined method for treating hormono-dependent disorders with exemestane
BRPI0207961B8 (pt) 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
KR100861466B1 (ko) 2001-04-24 2008-10-02 메르크 파텐트 게엠베하 항혈관형성제 및 ＴＮＦα를 이용한 병용 요법
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
JP2004527568A (ja) * 2001-05-03 2004-09-09 エフ．ホフマン−ラ　ロシュ　アーゲー ゼラチナーゼインヒビターと抗腫瘍剤との組み合わせ、およびその使用
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
EP1408973A2 (en) * 2001-07-23 2004-04-21 Epidauros Biotechnologie AG Means and methods for improved treatment of cancer based on mrp1
US7345088B2 (en) * 2001-10-19 2008-03-18 Penn State Research Foundation Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
NZ532418A (en) * 2001-10-25 2007-02-23 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent
ATE345130T1 (de) * 2001-12-03 2006-12-15 Bayer Pharmaceuticals Corp Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
AU2003206068A1 (en) 2002-03-01 2003-09-16 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
AU2003217930A1 (en) * 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1485131A1 (en) * 2002-03-08 2004-12-15 Novartis AG Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
BR0312736A (pt) * 2002-07-17 2005-04-26 Warner Lambert Co Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
MXPA05000722A (es) * 2002-07-17 2005-04-08 Warner Lambert Co Combinacion de un inhibidor alosterico carboxilico de la metaloproteinasa-13 de la matriz con un inhibidor selectivo de la ciclooxigenasa-2 que no es celecoxib o valdecoxib.
RS20050106A (en) * 2002-08-19 2007-11-15 Pfizer Products Inc., Combination therapy for hyperproliferative diseases
ES2666694T3 (es) 2002-09-06 2018-05-07 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
BR0317548A (pt) 2002-12-19 2005-11-22 Pfizer Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
WO2004082689A1 (en) * 2003-03-18 2004-09-30 Pharmacia Italia Spa Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor
DE10313272A1 (de) * 2003-03-24 2004-10-21 Baxter Healthcare S.A. Verwendung von Miltefosine zur Behandlung von aktinischer oder multiplen aktinischer Keratosen
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
DE602004017479D1 (de) 2003-08-29 2008-12-11 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
JP5015601B2 (ja) 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
UA82577C2 (en) 2003-12-23 2008-04-25 Пфайзер Инк. Quinoline derivatives
EP2803357B1 (en) 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
RS51362B (en) 2004-08-26 2011-02-28 Pfizer Inc. ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
EP1859797A4 (en) * 2005-02-28 2011-04-13 Eisai R&D Man Co Ltd NEW SIMULTANEOUS USE OF A SULPHONAMIDE COMPOUND AND A MEDIUM AGAINST CANCER
US7399335B2 (en) * 2005-03-22 2008-07-15 H.C. Starck Inc. Method of preparing primary refractory metal
ES2425396T3 (es) 2006-01-18 2013-10-15 Merck Patent Gmbh Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
DE102006037158A1 (de) * 2006-08-02 2008-02-14 Bioxsys Gmbh Verfahren zur Feststellung der Sensitivität von Tumoren gegenüber Capecitabin und Testkit
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2084267B1 (en) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
JP5079023B2 (ja) * 2007-03-23 2012-11-21 エフ．ホフマン−ラ ロシュ アーゲー 肺癌用マーカーとしてのａｐｅｘ
WO2008138200A1 (en) * 2007-05-11 2008-11-20 Hong Kong University Of Science & Technology Nmda and mc receptor antagonists exhibiting neuroprotective and memory enhancing activities
CA2705916C (en) * 2007-11-16 2016-01-05 Ube Industries, Ltd. Benzazepinone compound
NZ586909A (en) 2008-01-23 2012-05-25 Herlev Hospital Ykl-40 as a general marker for non-specific disease
US20110070601A1 (en) * 2008-01-23 2011-03-24 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
BRPI0911105B1 (pt) 2008-04-18 2022-11-08 Reata Pharmaceuticals, Inc Compostos contendo um farmacóforo anti-inflamatório, composição farmacêutica, bem como seus usos
WO2010028066A2 (en) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
NZ592241A (en) 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) * 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
ES2507145T3 (es) * 2009-05-14 2014-10-14 Arizona Board Of Regents On Behalf Of University Of Arizona Diagnóstico y tratamientos del carcinoma, basado en el genotipo de ODC1
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
EP3150610B1 (en) 2010-02-12 2019-07-31 Pfizer Inc Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US8515525B2 (en) * 2011-08-16 2013-08-20 Women's Imaging Solutions Enterprises Llc Skin adhesive agent for mammography procedures
JP6426001B2 (ja) 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
MX2015000794A (es) 2012-07-18 2015-10-12 Univ Saint Louis Derivados de aminoácido beta como antagonistas de integrina.
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
TWI646091B (zh) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 鹽類及晶形
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014150996A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Cancer treatment
HUE057203T2 (hu) 2013-09-24 2022-04-28 Fujifilm Corp Új nitrogén-tartalmú vegyület vagy sója, vagy azok fémkomplexe
US20170065723A1 (en) * 2013-09-27 2017-03-09 Cerulean Pharma Inc. Treatment of cancer
WO2015108595A1 (en) 2014-01-15 2015-07-23 Nikolai Khodarev Anti-tumor therapy
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
CN108366982A (zh) 2015-10-30 2018-08-03 癌症预防制药股份有限公司 依氟鸟氨酸和舒林酸，固定剂量的组合制剂
US9782370B2 (en) * 2015-12-21 2017-10-10 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
KR20180107121A (ko) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체
WO2017155935A1 (en) * 2016-03-07 2017-09-14 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
US10668039B2 (en) 2016-09-02 2020-06-02 The Children's Medical Center Corporation Methods for treatment of adenoid cystic carcinoma
NZ752894A (en) 2016-10-06 2023-05-26 Orbus Therapeutics Inc Formulations for administration of eflornithine
CN106389429A (zh) * 2016-12-02 2017-02-15 郑州莉迪亚医药科技有限公司 一种治疗老年痴呆症的西药组合物及其应用
WO2019040319A1 (en) * 2017-08-25 2019-02-28 The Regents Of The University Of California METHODS OF ENHANCING ANTICANCER CHEMOTHERAPY
CN111777615B (zh) * 2020-07-20 2022-04-19 济南大学 一种检测环氧合酶2的光动力治疗探针及其制备
CN114767868B (zh) * 2022-03-30 2023-04-18 宁夏医科大学 Cox-2抑制剂与化疗药物在制备抗肿瘤药物中的应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US5039805A (en) 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US5686568A (en) 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregration inhibitors
US5061693A (en) 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2037153A1 (en) 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5721210A (en) 1990-07-09 1998-02-24 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5229366A (en) 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5294713A (en) 1991-08-23 1994-03-15 Takeda Chemical Industries, Ltd. 2-piperazinone compounds and their use
US5674865A (en) 1991-10-18 1997-10-07 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa
CA2078817A1 (en) 1991-10-18 1993-04-19 Beat A. Imhof Anti-.alpha.6-integrin-antibodies
JPH07103148B2 (ja) 1991-12-16 1995-11-08 株式会社ディ・ディ・エス研究所 アントラサイクリン−マクロライド複合体
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5225531A (en) 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val
US5491129A (en) 1992-07-30 1996-02-13 Yeda Research And Development Co. Ltd. Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
US5629343A (en) * 1992-10-02 1997-05-13 Merck & Co., Inc. N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
JPH06116289A (ja) 1992-10-09 1994-04-26 Fuji Photo Film Co Ltd 細胞接着性ペプチド配列複合体とその用途
JPH08503475A (ja) * 1992-11-25 1996-04-16 メルク エンド カンパニー インコーポレーテッド 抗変性活性剤としてのカルボキシ−ペプチジル誘導体
TW301607B (tr) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
DE4310643A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE4310632A1 (de) 1993-04-01 1994-10-06 Merck Patent Gmbh Lineare Adhäsionsinhibitoren
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
DE4336758A1 (de) 1993-10-28 1995-05-04 Merck Patent Gmbh Lineare Adhäsionsinhibitoren
DK0656348T3 (da) 1993-12-03 2000-09-11 Hoffmann La Roche Eddikesyrederivater som medikamenter
JP3235319B2 (ja) 1994-01-14 2001-12-04 大正製薬株式会社 チアゾリン誘導体
JP3750144B2 (ja) 1994-01-14 2006-03-01 大正製薬株式会社 ３−アリールチアゾリン誘導体
DE4405378A1 (de) 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
JPH07285992A (ja) 1994-02-25 1995-10-31 Snow Brand Milk Prod Co Ltd 新規ペプチド
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE4415310A1 (de) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
US5741796A (en) 1994-05-27 1998-04-21 Merck & Co., Inc. Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
US5990112A (en) * 1996-06-18 1999-11-23 Affymax Technologies N.V. Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US5464855A (en) 1994-08-09 1995-11-07 Warner-Lambert Company Thiophene-2-carboxamidotetrazoles and pharmaceutical use thereof
US5639726A (en) 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
ES2123889T3 (es) 1994-11-02 1999-01-16 Merck Patent Gmbh Antagonistas de receptores de adhesion.
DE4439846A1 (de) 1994-11-08 1996-05-09 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
JPH08183752A (ja) 1994-12-28 1996-07-16 Sumitomo Pharmaceut Co Ltd シクロヘキサン誘導体
JPH08183788A (ja) 1994-12-28 1996-07-16 Sumitomo Pharmaceut Co Ltd １−オキサ−６−アザスピロ〔２．５〕オクタン誘導体
DE19504954A1 (de) 1995-02-15 1996-08-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
ATE203234T1 (de) 1995-08-30 2001-08-15 Searle & Co Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
US6013651A (en) 1995-08-30 2000-01-11 G. D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof
US6100423A (en) 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
DE19534016A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Biotinderivate
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0765660A3 (en) 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules comprising 2-piperazinone-1-acetic acid compounds
DE19539091A1 (de) 1995-10-20 1997-04-24 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
ES2193615T3 (es) 1995-10-25 2003-11-01 Senju Pharma Co .nhibidor de la angiogenesis.
TR199800990T2 (tr) * 1995-12-08 1998-07-21 Agouron Pharmaceuticals, Inc. Metaloproteinaz inhibitörleri, bunlari içeren farmasötik bilesimler, bunlarin farmasötik kullanimlari ve bunlarin üretiminde kullanilabilecek yöntemler ve ara ürünler.
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
DE19626701A1 (de) 1996-07-03 1998-01-08 Hoechst Ag Neue Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
PT796855E (pt) 1996-03-20 2002-07-31 Hoechst Ag Inibicao da reabsorcao nos ossos e antagonistas de vitronectina
ATE204857T1 (de) 1996-03-29 2001-09-15 Searle & Co Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
EP0889876B1 (en) 1996-03-29 2001-07-25 G.D. SEARLE & CO. Meta-substituted phenylene sulphonamide derivatives
EP0894084B1 (en) 1996-03-29 2002-06-26 G.D. Searle & Co. Cinnamic acid derivatives and their use as integrin antagonists
EP0891325B1 (en) 1996-03-29 2002-02-06 G.D. Searle & Co. Para-substituted phenylpropanoic acid derivatives as integrin antagonists
EP0889875B1 (en) 1996-03-29 2001-06-20 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
DE19613933A1 (de) 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
DE19654483A1 (de) 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate
WO1998002410A1 (en) 1996-07-12 1998-01-22 G.D. Searle & Co. Asymetric synthesis of chiral beta-amino acids
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TWI235060B (en) * 1996-10-15 2005-07-01 Searle & Co Pharmaceutical compositions comprising substituted pyrazolyl benzenesulfonamide derivatives for use in treating or preventing an epithelial cell-derived neoplasia
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
CN1247470A (zh) * 1996-11-19 2000-03-15 G·D·瑟尔公司 使用环加氧酶－2抑制剂作为抗血管发生剂的方法
DE69739295D1 (de) 1996-12-09 2009-04-23 Merck Patent Gmbh Löslicher, rekombinanter alphaV beta3 Adhäsionsrezeptor
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
CA2277273C (en) * 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
AU1110799A (en) * 1997-10-29 1999-05-17 Warner-Lambert Company Method of inhibiting metastases of cancer cells
US6541489B1 (en) * 1997-11-14 2003-04-01 G. D. Searle & Company Aromatic sulfone hydroxamic acid metalloprotease inhibitor
EP1040111B1 (en) * 1997-12-17 2005-06-22 Merck & Co., Inc. Integrin receptor antagonists
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
SI0928793T1 (en) 1998-01-02 2002-10-31 F. Hoffmann-La Roche Ag Thiazole derivatives
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
EP1070060A1 (en) * 1998-04-10 2001-01-24 G.D. Searle & Co. Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
CA2338275A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents

Also Published As

Publication number Publication date
WO2000037107A3 (en) 2001-02-01
CA2356606A1 (en) 2000-07-06
JP2002533404A (ja) 2002-10-08
EP1140192A2 (en) 2001-10-10
CZ20012321A3 (cs) 2002-10-16
CN1371286A (zh) 2002-09-25
CA2356929A1 (en) 2000-07-06
NO20013156D0 (no) 2001-06-22
ZA200105120B (en) 2002-01-07
MXPA01006499A (es) 2002-04-08
US6689787B1 (en) 2004-02-10
EP1140177A2 (en) 2001-10-10
WO2000038717A3 (en) 2001-02-01
PL349216A1 (en) 2002-07-01
KR20010110310A (ko) 2001-12-12
CA2356302A1 (en) 2000-07-06
DE69930764D1 (de) 2006-05-18
JP2002533406A (ja) 2002-10-08
WO2000038715A2 (en) 2000-07-06
JP2002533407A (ja) 2002-10-08
JP2002533405A (ja) 2002-10-08
JP2002533387A (ja) 2002-10-08
WO2000038730A3 (en) 2000-11-02
JP2002533422A (ja) 2002-10-08
NO20013155D0 (no) 2001-06-22
JP2002532563A (ja) 2002-10-02
WO2000038717A2 (en) 2000-07-06
AU2207000A (en) 2000-07-31
CA2356459A1 (en) 2000-07-06
EP1140179A2 (en) 2001-10-10
WO2000038719A1 (en) 2000-07-06
WO2000038718A2 (en) 2000-07-06
EP1140194A2 (en) 2001-10-10
CA2356402A1 (en) 2000-07-06
AU2713600A (en) 2000-07-31
CA2356462A1 (en) 2000-07-06
WO2000038665A2 (en) 2000-07-06
EA006294B1 (ru) 2005-10-27
EA200100572A1 (ru) 2002-02-28
IL143870A0 (en) 2002-04-21
WO2000038730A2 (en) 2000-07-06
BR9916518A (pt) 2002-01-29
CN1346282A (zh) 2002-04-24
WO2000038786A2 (en) 2000-07-06
AU2209800A (en) 2000-07-31
CA2356748A1 (en) 2000-07-06
NO20013155L (no) 2001-08-22
ZA200105055B (en) 2002-09-20
HUP0104814A2 (hu) 2002-04-29
EP1140193A2 (en) 2001-10-10
WO2000038665A3 (en) 2000-11-16
WO2000038718A3 (en) 2000-11-09
JP2002533416A (ja) 2002-10-08
ATE322290T1 (de) 2006-04-15
AU783992B2 (en) 2006-01-12
WO2000038786A3 (en) 2001-03-08
WO2000038715A3 (en) 2001-01-04
EP1140178A2 (en) 2001-10-10
AU2713500A (en) 2000-07-31
IL143901A0 (en) 2002-04-21
KR20010109275A (ko) 2001-12-08
EP1140192B1 (en) 2006-04-05
AU2380500A (en) 2000-07-31
AU2210400A (en) 2000-07-31
EP1140183A1 (en) 2001-10-10
HUP0104747A2 (hu) 2002-04-29
CZ20012320A3 (cs) 2002-10-16
CN1398189A (zh) 2003-02-19
EA200100573A1 (ru) 2002-02-28
HUP0104747A3 (en) 2002-12-28
EP1140182A2 (en) 2001-10-10
WO2000037107A2 (en) 2000-06-29
CA2356426A1 (en) 2000-06-29
AU2592600A (en) 2000-07-31
AU2593600A (en) 2000-07-12
HUP0104814A3 (en) 2003-03-28
NO20013156L (no) 2001-08-23
PL350291A1 (en) 2002-12-02
BR9916536A (pt) 2002-01-02

Similar Documents

Publication Publication Date Title
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
SE9703693D0 (sv) Novel combination
DK1140181T3 (da) Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
TR199901703T2 (tr) Siklooksijenaz-2 inhibitörlerini anti-anjiyojenik ajanlar olarak kullanma yöntemi.
MXPA05011501A (es) Combinacion terapeutica de un inhibidor de cox-2 y un inhibidor de aromatasa.
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
DE69930844D1 (de) Inhibitoren von mycobakterien
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита
UA32314A (uk) Спосіб лікування некротичного панкреатиту